Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: Potential partners in vascular calcifications

Nephrology Dialysis Transplantation

Volumn 30, Issue 8, 2015, Pages 1345-1356

  Morena, Marion ^a,b,c   Jaussent, Isabelle ^c,d   Dupuy, Anne Marie ^a   Bargnoux, Anne Sophie ^a,c   Kuster, Nils ^a,c   Chenine, Leila ^a   Leray Moragues, Hélène ^a   Klouche, Kada ^a,c   Vernhet, Hélène ^a   Canaud, Bernard ^b,c,e   Cristol, Jean Paul ^a,b,c  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b Institut de Recherche et de Formation en Dialyse   (France)

^c UNIV MONTPELLIER   (France)

^d INSERM U1061   (France)

^e FRESENIUS MEDICAL CARE   (Germany)

Author keywords

CAC; chronic kidney disease; DKK1; OPG; SOST

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOLOGICAL MARKER; DICKKOPF 1 PROTEIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; SCLEROSTIN; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD VESSEL CALCIFICATION; BODY MASS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MULTIDETECTOR COMPUTED TOMOGRAPHY; POPULATION RESEARCH; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SCORING SYSTEM; SEX DIFFERENCE; SMOKING HABIT; VERY ELDERLY; ADVERSE EFFECTS; BLOOD; BONE REMODELING; CORONARY ARTERY DISEASE; DRUG EFFECTS; GENETIC MARKER; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; VASCULAR CALCIFICATION;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84939604497     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv081     Document Type: Article

References (44)

1. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740
2. Chiu YW, Adler SG, Budoff MJ et al. Coronary artery calcification and mortality in diabetic patients with proteinuria. Kidney Int 2010; 77: 1107-1114
3. HaasMH. The risk of death in patients with a high coronary calcification score: does it include predialysis patients? Kidney Int 2010; 77: 1057-1059
4. London GM, Marchais SJ, Guerin AP et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-531
5. London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004; 15: 1943-1951
6. Trouvin A, GoëbV. Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 2010; 19: 345-354
7. Morena M, Dupuy AM, Jaussent I et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009; 24: 3389-3397
8. Nitta K, Akiba T, Uchida K et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1886-1889
9. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148: 2635-2643
10. Hampson G, Edwards S, Conroy S et al. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in postmenopausal women. Bone 2013; 56: 42-47
11. Morales-Santana S, Garcia-Fontana B, Garcia-Martin A et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 2013; 36: 1667-1674
12. Didangelos A, Yin X, Mandal K et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011; 10: M111.008128
13. Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 2002; 14: 238-242
14. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
15. Boutten A, Bargnoux AS, CarlierMCet al. Enzymatic but not compensated Jaffe methods reach the desirable specifications of NKDEP at normal levels of creatinine. Results of the French multicentric evaluation. Clin Chim Acta 2013; 419: 132-135
16. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
17. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. NICE National Institute for Health and Care Excellence Clinical Guideline 2014; 182
18. Kuster N, Cristol JP, Cavalier E et al. Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation. Clin Chim Acta 2014; 428: 89-95
19. Avignon A, Sultan A, Piot C et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type-2 diabetic patients. Diabetes Care 2005; 28: 2176-2180
20. Maïmoun L, Couret I, Mariano-Goulart D et al. Changes in osteoprotegerin/RANKL system, bone mineral density and bone biochemical markers in patients with recent spinal cord injury. Calcif Tissue Int 2005; 76: 404-411
21. Agatston AS, Janowitz WR, Hildner FJ et al. Quantification of coronary artery calcium using ultrafast computed tomography. JAmColl Cardiol 1990; 15: 827-832
22. Brindis RG, Douglas PS, Hendel RC et al. ACCF/ASNC appropriateness criteria for single-photon emission computed tomography myocardial perfusion imaging (SPECT MPI): a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group and the American Society of Nuclear Cardiology endorsed by the American Heart Association. J Am Coll Cardiol 2005; 46: 1587-1605
23. Greenland P, Bonow RO, Brundage BH et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHAWriting Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007; 49: 378-402
24. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964-974
25. Royston P, Sauerbrei W. Building multivariable regression models with continuous covariates in clinical epidemiology-with an emphasis on fractional polynomials. Methods Inf Med 2005; 44: 561-571
26. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 76: S1-S130
27. Morena M, Jaussent I, Halkovich A et al. Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients. PLoS One 2012; 7: e36175
28. Pelletier S, Dubourg L, Carlier MC et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823
29. Cejka D, Marculescu R, Kozakowski N et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248-255
30. Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
31. Kim SH, Yoon SY, Lim SK et al. The effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes. Int J Endocrinol 2014; 2014: 715908
32. Viapiana O, Fracassi E, Troplini S et al. Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 2013; 92: 324-329
33. Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480
34. Kulkarni NH, Halladay DL, Miles RR et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 2005; 95: 1178-1190
35. Guo J, Liu M, Yang D et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 2010; 11: 161-171
36. Anastasilakis AD, Polyzos SA, Avramidis A et al. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. Clin Endocrinol (Oxf) 2010; 72: 752-757
37. Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in longhaemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955
38. Nitta K, Akiba T, Uchida K et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003; 42: 303-309
39. Claes KJ, Viaene L, Heye S, et al. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 2013; 98: 3221-3228
40. Brandenburg VM, Kramann R, Koos R et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a crosssectional study. BMC Nephrol 2013; 14: 219
41. Kanbay M, Siriopol D, Saglam M et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab 2014; 99: E1854-E1861
42. Register TC, Hruska KA, Divers J et al. Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes. J Clin Endocrinol Metab 2013; 98: E60-E65
43. Kim KI, Park KU, Chun EJ et al. A novel biomarker of coronary atherosclerosis: serum DKK1 concentration correlates with coronary artery calcification and atherosclerotic plaques. J Korean Med Sci 2011; 26: 1178-1184
44. Tanaka H, Iwasaki Y, Yamato H et al. P-Cresyl sulfate induces osteoblast dysfunction through activating JNK and p38 MAPK pathways. Bone 2013; 56: 347-354